Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Curran

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
American Journal of Hematology|September 10, 2024
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional studyTalha Badar, Ravi Narra, Alice S Mims, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
Leukemia & Lymphoma|April 9, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Razan Mohty, Ravi Narra, Alice S Mims, et al.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
JCO Oncology Practice|January 22, 2024
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALLJulie A Wolfson, Allison C Grimes, Michelle Nuno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
JNCI Cancer Spectrum|April 16, 2025
Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemiaJulie A Wolfson, Allison C Grimes, Michelle M Nuño, et al.
JCI Insight|April 22, 2024
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemiaOla A Elgamal, Sydney Fobare, Sandip Vibhute, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
American Journal of Hematology|September 10, 2024
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional studyTalha Badar, Ravi Narra, Alice S Mims, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
Leukemia & Lymphoma|April 9, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Razan Mohty, Ravi Narra, Alice S Mims, et al.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
JCO Oncology Practice|January 22, 2024
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALLJulie A Wolfson, Allison C Grimes, Michelle Nuno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
JNCI Cancer Spectrum|April 16, 2025
Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemiaJulie A Wolfson, Allison C Grimes, Michelle M Nuño, et al.
JCI Insight|April 22, 2024
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemiaOla A Elgamal, Sydney Fobare, Sandip Vibhute, et al.
Pageof 5